ATE303156T1 - Verwendung von gnrh-analogue zur behandlung der harninkontinenz - Google Patents

Verwendung von gnrh-analogue zur behandlung der harninkontinenz

Info

Publication number: ATE303156T1
Authority: AT; Austria
Prior art keywords: urinary incontinence; gnrh analogue; treat urinary; gnrh; analogue
Prior art date: 2000-10-30

Application number

AT01975948T

Other languages

English (en)

Inventor

Susi Arnold

Iris Reichler

Madeleine Hubler

Original Assignee

Univ Zuerich

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-30

Filing date

2001-10-26

Publication date

2005-09-15

2001-10-26 Application filed by Univ Zuerich filed Critical Univ Zuerich

2005-09-15 Application granted granted Critical

2005-09-15 Publication of ATE303156T1 publication Critical patent/ATE303156T1/de

Links

206010046543 Urinary incontinence Diseases 0.000 title abstract 2
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 title 1
102100024028 Progonadoliberin-1 Human genes 0.000 title 1
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 abstract 1
206010060800 Hot flush Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
230000001850 reproductive effect Effects 0.000 abstract 1
230000009758 senescence Effects 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Electrotherapy Devices (AREA)

AT01975948T 2000-10-30 2001-10-26 Verwendung von gnrh-analogue zur behandlung der harninkontinenz ATE303156T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00811011		2000-10-30
PCT/CH2001/000636 WO2002036144A1 (en)	2000-10-30	2001-10-26	Gnrh analogues for treatment of urinary incontinence

Publications (1)

Publication Number	Publication Date
ATE303156T1 true ATE303156T1 (de)	2005-09-15

Family

ID=8174999

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01975948T ATE303156T1 (de)	2000-10-30	2001-10-26	Verwendung von gnrh-analogue zur behandlung der harninkontinenz

Country Status (9)

Country	Link
US (2)	US7498303B2 (de)
EP (1)	EP1330257B1 (de)
JP (1)	JP2004512369A (de)
AT (1)	ATE303156T1 (de)
AU (1)	AU2001295359A1 (de)
BR (1)	BR0115067A (de)
CA (1)	CA2427731A1 (de)
DE (1)	DE60113142T2 (de)
WO (1)	WO2002036144A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7439241B2 (en)	2003-05-27	2008-10-21	Galderma Laboratories, Inc.	Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en)	2004-01-22	2010-10-12	Vicept Therapeutics, Inc.	Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
GT200500315A (es) *	2004-11-02	2006-06-06		Formas de dosificacion oral solidas que contienen una dosis baja de estradiol
BRPI0611390A2 (pt) *	2005-06-01	2010-09-08	Pfizer Prod Inc	composições de vacina e uso de composições compreendendo vacina anti-lhrh na preparação de um medicamento para tratar incontinência urinária
EP1967202A1 (de) *	2007-03-05	2008-09-10	AEterna Zentaris GmbH	Verwendung von LHRH-Antagonisten zur Behandlung von Symptomen der unteren Harnwege, insbesondere Blasen- und/oder Detrusorhyperaktivität
EP2266568A1 (de)	2009-05-26	2010-12-29	Æterna Zentaris GmbH	Pharmazeutische Zubereitung enthaltend LHRH-Antagonisten und PDE V Hemmern zur Behandlung von Sexualhormon abhängigen Erkrankungen
EP2266567A1 (de)	2009-05-26	2010-12-29	Æterna Zentaris GmbH	Pharmazeutische Zubereitung enthaltend Cetrorelix und PDE V Hemmern zur Behandlung von Sexualhormon abhängige Erkrankungen
ES2533584T3 (es) *	2010-04-15	2015-04-13	Bayer Intellectual Property Gmbh	Formas de dosificación oral sólidas de dosis baja para TSH
AU2011252763B2 (en) *	2010-05-14	2012-12-20	Charlotte L. Keating	A method of treatment and diagnosis
RS62297B1 (sr)	2011-11-23	2021-09-30	Therapeuticsmd Inc	Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US8871261B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Cancer treatments and compositions for use thereof
US8871258B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Treatment and prevention of learning and memory disorders
US8871257B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871260B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Methods and compositions for muscular and neuromuscular diseases
US8871254B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871259B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Techniques and systems for treatment of neuropathic pain and other indications
US8871255B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Treatment of skin and soft tissue infection with nitric oxide
US8871256B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871262B2 (en)	2012-09-19	2014-10-28	Transdermal Biotechnology, Inc.	Compositions and methods for treatment of osteoporosis and other indications
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9295647B2 (en)	2013-03-13	2016-03-29	Transdermal Biotechnology, Inc.	Systems and methods for delivery of peptides
US20140271731A1 (en)	2013-03-13	2014-09-18	Transdermal Biotechnology, Inc.	Cardiovascular disease treatment and prevention
US9314433B2 (en)	2013-03-13	2016-04-19	Transdermal Biotechnology, Inc.	Methods and systems for treating or preventing cancer
US9724419B2 (en)	2013-03-13	2017-08-08	Transdermal Biotechnology, Inc.	Peptide systems and methods for metabolic conditions
US9314417B2 (en)	2013-03-13	2016-04-19	Transdermal Biotechnology, Inc.	Treatment of skin, including aging skin, to improve appearance
US9295636B2 (en)	2013-03-13	2016-03-29	Transdermal Biotechnology, Inc.	Wound healing using topical systems and methods
US9339457B2 (en)	2013-03-13	2016-05-17	Transdermal Biotechnology, Inc.	Cardiovascular disease treatment and prevention
US9849160B2 (en)	2013-03-13	2017-12-26	Transdermal Biotechnology, Inc.	Methods and systems for treating or preventing cancer
US20140271938A1 (en)	2013-03-13	2014-09-18	Transdermal Biotechnology, Inc.	Systems and methods for delivery of peptides
US9295637B2 (en)	2013-03-13	2016-03-29	Transdermal Biotechnology, Inc.	Compositions and methods for affecting mood states
US9687520B2 (en)	2013-03-13	2017-06-27	Transdermal Biotechnology, Inc.	Memory or learning improvement using peptide and other compositions
US9750787B2 (en)	2013-03-13	2017-09-05	Transdermal Biotechnology, Inc.	Memory or learning improvement using peptide and other compositions
US9393265B2 (en)	2013-03-13	2016-07-19	Transdermal Biotechnology, Inc.	Wound healing using topical systems and methods
US9314422B2 (en)	2013-03-13	2016-04-19	Transdermal Biotechnology, Inc.	Peptide systems and methods for metabolic conditions
US9387159B2 (en)	2013-03-13	2016-07-12	Transdermal Biotechnology, Inc.	Treatment of skin, including aging skin, to improve appearance
US9320758B2 (en)	2013-03-13	2016-04-26	Transdermal Biotechnology, Inc.	Brain and neural treatments comprising peptides and other compositions
US9320706B2 (en)	2013-03-13	2016-04-26	Transdermal Biotechnology, Inc.	Immune modulation using peptides and other compositions
US9241899B2 (en)	2013-03-13	2016-01-26	Transdermal Biotechnology, Inc.	Topical systems and methods for treating sexual dysfunction
US9314423B2 (en)	2013-03-13	2016-04-19	Transdermal Biotechnology, Inc.	Hair treatment systems and methods using peptides and other compositions
US9393264B2 (en)	2013-03-13	2016-07-19	Transdermal Biotechnology, Inc.	Immune modulation using peptides and other compositions
RU2016143081A (ru)	2014-05-22	2018-06-26	Терапьютиксмд, Инк.	Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
US9931349B2 (en)	2016-04-01	2018-04-03	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
US10286077B2 (en)	2016-04-01	2019-05-14	Therapeuticsmd, Inc.	Steroid hormone compositions in medium chain oils
CN110234336A (zh) *	2017-01-31	2019-09-13	维鲁公司	用于促性腺激素释放激素(GnRH)拮抗剂的长效释放的组合物和方法
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5434136A (en) *	1990-12-14	1995-07-18	Mathias; John R.	Treatment of motility disorders with a GNRH analog
US5211952A (en) *	1991-04-12	1993-05-18	University Of Southern California	Contraceptive methods and formulations for use therein
US5340585A (en) *	1991-04-12	1994-08-23	University Of Southern California	Method and formulations for use in treating benign gynecological disorders
US5340805A (en) *	1992-12-10	1994-08-23	Sterling Winthrop Inc.	Danazol for treatment of urinary incontinence
US5681817A (en) *	1994-02-04	1997-10-28	The Medical College Of Hampton Roads	Treatment of ovarian estrogen dependent conditions
AUPN366795A0 (en) *	1995-06-20	1995-07-13	Peptide Technology Limited	Formulation for preventing reproductive function
US5789442A (en) *	1996-01-18	1998-08-04	Schering Aktiengesellschaft	Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
NZ334236A (en) *	1996-08-30	2000-06-23	Peptech Ltd	Composition comprising GnRH, lecithin and stearin
US6416778B1 (en) *	1997-01-24	2002-07-09	Femmepharma	Pharmaceutical preparations and methods for their regional administration
US6051558A (en) *	1997-05-28	2000-04-18	Southern Biosystems, Inc.	Compositions suitable for controlled release of the hormone GnRH and its analogs
CA2306110A1 (en) *	1997-10-17	1999-04-29	Mochida Pharmaceutical Co., Ltd.	Therapeutic agent of uterine leiomyoma, containing dienogest as effective ingredient
JP2002512976A (ja)	1998-04-27	2002-05-08	プレーシスファーマスーティカルズインコーポレイテッド	のぼせおよび女性化乳房を処置するための方法
US6586000B2 (en) *	1999-12-16	2003-07-01	Dermatrends, Inc.	Hydroxide-releasing agents as skin permeation enhancers
GB0015246D0 (en) *	2000-06-22	2000-08-16	Astrazeneca Ab	Method for the treatment of urinary incontinence
JP3878178B2 (ja) *	2001-12-28	2007-02-07	武田薬品工業株式会社	排尿障害予防治療剤

2001
- 2001-10-26 EP EP01975948A patent/EP1330257B1/de not_active Expired - Lifetime
- 2001-10-26 AU AU2001295359A patent/AU2001295359A1/en not_active Abandoned
- 2001-10-26 AT AT01975948T patent/ATE303156T1/de not_active IP Right Cessation
- 2001-10-26 DE DE60113142T patent/DE60113142T2/de not_active Expired - Lifetime
- 2001-10-26 CA CA002427731A patent/CA2427731A1/en not_active Abandoned
- 2001-10-26 US US10/415,519 patent/US7498303B2/en not_active Expired - Fee Related
- 2001-10-26 WO PCT/CH2001/000636 patent/WO2002036144A1/en not_active Ceased
- 2001-10-26 JP JP2002538955A patent/JP2004512369A/ja not_active Withdrawn
- 2001-10-26 BR BR0115067-7A patent/BR0115067A/pt not_active Application Discontinuation
2009
- 2009-01-20 US US12/356,406 patent/US20090246209A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1330257A1 (de)	2003-07-30
AU2001295359A1 (en)	2002-05-15
EP1330257B1 (de)	2005-08-31
US20040023878A1 (en)	2004-02-05
US20090246209A1 (en)	2009-10-01
JP2004512369A (ja)	2004-04-22
BR0115067A (pt)	2004-04-06
DE60113142T2 (de)	2006-07-06
US7498303B2 (en)	2009-03-03
CA2427731A1 (en)	2002-05-10
DE60113142D1 (de)	2005-10-06
WO2002036144A1 (en)	2002-05-10

Legal Events

Date	Code	Title	Description
2006-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60113142D1 (de)	2005-10-06	Verwendung von gnrh-analogue zur behandlung der harninkontinenz
GB9807639D0 (en)	1998-06-10	Anti-inflammatory agents
DE69618787D1 (de)	2002-03-14	Topische zusammensetzungen mit verbessertem hautgefühl
EP1515724A4 (de)	2005-08-17	Mitotische kinesin-hemmer
DK0755249T3 (da)	2004-07-26	Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
ATE456369T1 (de)	2010-02-15	Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
DK0909556T3 (da)	2004-02-02	Rosaceae-ekstrakt som bradykininantagonist
ATE214272T1 (de)	2002-03-15	Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
MXPA03001643A (es)	2004-05-14	Composiciones y metodos para el diagnostico y tratamiento de tumores.
ATE359808T1 (de)	2007-05-15	Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE234614T1 (de)	2003-04-15	Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
TR200200278T2 (tr)	2002-06-21	Kalsilitik bileşimler
DE50106546D1 (de)	2005-07-21	Zubereitung von cimicifuga racemosa zur behandlung der inkontinenz
DE60119285D1 (de)	2006-06-08	Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall
ID27755A (id)	2001-04-26	Komposisi parfum
ATE458495T1 (de)	2010-03-15	Therapeutische zubereitung für autoimmune erkrankungen
ATE278401T1 (de)	2004-10-15	Verwendung von riluzol zur behandlung von akustischen traumazuständen
ATE236633T1 (de)	2003-04-15	Topische verwendung von loperamid zur behandlung mikrobieller infektionen
MXPA02011162A (es)	2003-07-28	Proteina cln2 recombinante de humano y metodos para su reduccion y uso.
ATE345121T1 (de)	2006-12-15	Verwendung von konjugierter linolsäure zur behandlung der erkältung
WO2002034210A3 (fr)	2002-06-27	Utilisation de l'association d'au moins un carotenoide et de vitamine c pour traiter les signes cutanes du vieillissement
ATE291425T1 (de)	2005-04-15	R-eliprodil zur behandlung von glaucoma
AU8988901A (en)	2002-03-26	Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids
DE50202941D1 (de)	2005-06-02	Verwendung von extrakten aus cimicifuga-arten als organselektives arzneimittel zur behandlung von sexualhormonabhängigen erkrankungen des urogenitaltraktes
DE60210313D1 (de)	2006-05-18	Verwendung von dattelkern-extrakt zur minderung der anzeichen der hautalterung